Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Curemark, LLC

http://www.curemark.com

Latest From Curemark, LLC

Autism Feedback To FDA: Focus On Communication, Redefine 'Irritability'

US FDA’s 22nd Patient-Focused Drug Development meeting focused on the challenging disease of autism. It also showed how far FDA has come in embracing the patient-input process over the past five years.

Drug Approval Standards FDA

FDA Autism Meeting: Will It Stray From Symptoms And Treatments To Causation?

US agency may face challenge of keeping May 4 meeting on patient-focused drug development focused on autism disease burden and current therapeutic approaches rather than vaccine safety.

Regulation Drug Approval Standards

PIPELINE WATCH: Four Approvals, Six Filings And Three Launches

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Pipeline Watch Approvals

EMA Autism Guidance Pushes Sponsors To Tackle Core Symptoms

While short-term efficacy in core symptoms should be demonstrated first, EMA draft drug development guidance also calls for a showing of positive effect on global function and maintenance of long-term efficacy.

BioPharmaceutical Europe
See All

Company Information

UsernamePublicRestriction

Register